Literature DB >> 29315136

Renal Replacement Therapy in the Critically Ill Child.

Claire A Westrope1, Sarah Fleming2, Melpo Kapetanstrataki2, Roger C Parslow3, Kevin P Morris4.   

Abstract

OBJECTIVES: Although renal replacement therapy is widely used in critically ill children, there have been few comprehensive population-based studies of its use. This article describes renal replacement therapy use, and associated outcomes, in critically ill children across the United Kingdom in the largest cohort study of this patient group.
DESIGN: A retrospective observational study using prospectively collected data.
SETTING: Data from the Pediatric Intensive Care Audit Network database which collects data on all children admitted to U.K. PICUs. PATIENTS: Children (< 16 yr) in PICU who received renal replacement therapy between January 1, 2005, and December 31, 2012, were identified.
INTERVENTIONS: Individual-level data including age, underlying diagnosis, modality (peritoneal dialysis and continuous extracorporeal techniques [continuous renal replacement therapy]), duration of renal replacement therapy, PICU length of stay, and survival were extracted.
MEASUREMENTS AND MAIN RESULTS: Three-thousand eight-hundred twenty-five of 129,809 PICU admissions (2.9%) received renal replacement therapy in 30 of 33 centers. Volumes of renal replacement therapy varied considerably from 0% to 8.6% of PICU admissions per unit, but volume was not associated with patient survival. Overall survival to PICU discharge (73.8%) was higher than previous reports. Mortality risk was related to age, with lower risk in older children compared with neonates (odds ratio, 0.6; 95% CI, 0.5-0.8) although mortality did not increase over the age of 1 year; mode of renal replacement therapy, with lower risk in peritoneal dialysis than continuous renal replacement therapy methodologies (odds ratio, 0.7; 0.5-0.9); duration of renal replacement therapy (odds ratio, 1.02/d; 95% CI, 1.01-1.04); and primary diagnosis, with the lowest survival in liver disease patients (53.9%).
CONCLUSIONS: This study describes current renal replacement therapy use across the United Kingdom and associated outcomes. We describe a number of factors associated with outcome, including age, underlying diagnosis, and renal replacement therapy modality which will need to be factored into future trial design.

Entities:  

Mesh:

Year:  2018        PMID: 29315136     DOI: 10.1097/PCC.0000000000001431

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  4 in total

1.  Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.

Authors:  Gideon Stitt; Jennifer Morris; Lindsay Schmees; Joseph Angelo; Ayse Akcan Arikan
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Epidemiology and Outcome of Critically Ill Pediatric Cancer and Hematopoietic Stem Cell Transplant Patients Requiring Continuous Renal Replacement Therapy: A Retrospective Nationwide Cohort Study.

Authors:  Paulien A M A Raymakers-Janssen; Marc R Lilien; Dick Tibboel; Martin C J Kneyber; Sandra Dijkstra; Job B M van Woensel; Joris Lemson; Karlien Cransberg; Marry M van den Heuvel-Eibrink; Roelie M Wösten-van Asperen
Journal:  Crit Care Med       Date:  2019-11       Impact factor: 7.598

3.  I-KID study protocol: evaluation of efficacy, outcomes and safety of a new infant haemodialysis and ultrafiltration machine in clinical use: a randomised clinical investigation using a cluster stepped-wedge design.

Authors:  Heather J Lambert; Shriya Sharma; John N S Matthews
Journal:  BMJ Paediatr Open       Date:  2021-10-18

4.  Identifying critically ill children at high risk of acute kidney injury and renal replacement therapy.

Authors:  Rachel J McGalliard; Stephen J McWilliam; Samuel Maguire; Caroline A Jones; Rebecca J Jennings; Sarah Siner; Paul Newland; Matthew Peak; Christine Chesters; Graham Jeffers; Caroline Broughton; Lynsey McColl; Steven Lane; Stephane Paulus; Nigel A Cunliffe; Paul Baines; Enitan D Carrol
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.